Comparative Pharmacology
Head-to-head clinical analysis: KEFLET versus SEFFIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KEFLET versus SEFFIN.
KEFLET vs SEFFIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Keflet (warfarin) inhibits vitamin K epoxide reductase, preventing the recycling of vitamin K and thereby reducing the synthesis of clotting factors II, VII, IX, and X in the liver.
SEFFIN is a brand name for cefazolin, a first-generation cephalosporin antibiotic. It inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It is bactericidal against susceptible organisms.
500 mg orally every 12 hours for 10-14 days; for uncomplicated UTI: 250 mg orally every 12 hours for 7 days.
1-2 g IV/IM every 6-8 hours; maximum 8 g/day.
None Documented
None Documented
0.5-1 hour; prolonged in renal impairment (up to 20-30 hours in ESRD).
Terminal elimination half-life is approximately 0.5-1 hour in adults with normal renal function; prolonged to 20-40 hours in severe renal impairment (CrCl <10 mL/min).
Renal (80-90% unchanged via glomerular filtration and tubular secretion); biliary/fecal < 5%.
Primarily renal (80-90% unchanged) via glomerular filtration and tubular secretion; minor biliary excretion (<5%) and fecal elimination.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic